LIMN Liminatus Pharma, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1971387 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,098.0%
TTM EPS YoY-860.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-471.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.12x
Interest coverage-53.78x
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-321.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | — | $2.69M |
| SG&A expense | $2.97M | $644,619 |
| Operating income | -$2.97M | -$3.33M |
| Interest expense | $215,903 | $338,882 |
| Net income | -$10.21M | -$3.55M |
| EBITDA | -$2.97M | — |
| EPS (basic) | -0.43 | -0.20 |
| EPS (diluted) | -0.43 | -0.20 |
| Weighted avg. shares (diluted) | 23.75M | 17.50M |
| Balance sheet | ||
| Cash & equivalents | $337,655 | $56,319 |
| Current assets | $500,574 | $5.28M |
| PP&E, net | $12,221 | $941 |
| Total assets | $512,795 | $5.41M |
| Current liabilities | $10.30M | $24.75M |
| Short-term debt | $1.44M | $19.97M |
| Total liabilities | $10.33M | $24.75M |
| Shareholders' equity | -$9.81M | -$19.34M |
| Shares outstanding | 27.06M | 17.50M |
| Cash flow statement | ||
| Operating cash flow | -$9.96M | -$1.45M |
| Capital expenditure | $13,108 | — |
| Free cash flow | -$9.98M | — |
| Investing cash flow | -$788,108 | -$2.85M |
| Financing cash flow | $11.03M | $3.92M |
| Depreciation & amortization | $1,828 | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.